ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

284
Analysis
Health Care • Hong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
bullish•Hang Seng Index
•19 Jul 2025 07:50

Hong Kong Single Stock Options Weekly (July 14 – 18): HSI at Fresh Highs But Option Volumes Lag

HSI extends its breakout with strong single stock and sector breadth but option volumes—particularly Calls—showed signs of hesitation.

Logo
John Ley
570 Views
Share
bullish•Cross Asset Strategy
•14 Jul 2025 09:03

Hong Kong Alpha Portfolio (June 2025)

The Hong Kong Alpha portfolio has significantly outperformed the Hong Kong indexes in June and since inception. Outperformance range is 17% to 23%...

Logo
326 Views
Share
•13 Jul 2025 08:30

APAC Healthcare Weekly (July 13) – Chugai, JCR, Cochlear, CStone, Celltrion, Glenmark, Lupin

Chugai entered inlicensing agreement. JCR Pharma and Glenmark stuck outlicensing deal. Cochlear got new product approval. CStone and Lupin found...

Logo
540 Views
Share
•08 Jul 2025 08:55

Genor Biopharma (6998 HK) - The Reverse Merger Will Unleash the Upside Potential of Valuation

​The merger will boost Genor's valuation and help Edding to go public. Future success hinges on pipeline quality. Valuation expected to reach...

Logo
498 Views
Share
•06 Jul 2025 08:30

APAC Healthcare Weekly (July 6)- Shionogi, Simcere, Wuxi XDC, Sino Bio, Apollo Hosp, Torrent Pharma

Simcere, CSPC, and Sino Bio got approvals for their new drugs in China. Apollo Hospital announced a demerger. Torrent is acquiring controlling...

Logo
678 Views
Share
x